U.S. market Open. Closes in 3 hours 12 minutes

LGND | Ligand Pharmaceuticals Incorporated Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for LGND we got that it has average fundamentals where Valuation is considered to be slightly overvalued, Profitability is very poor, Growth is very good and Health is confidently strong.

Valuation (50%)

Company Industry
P/E Ratio (TTM) 50.88 -23.05
PEG Ratio (TTM) -0.89 15.47
P/S Ratio (TTM) 15.30 49.46
P/B Ratio (TTM) 2.60 18.87
P/FCF Ratio (TTM) -351.18 -3.27
Price to 5YR AVG Earnings Ratio 14.30 -3.55
Price to 5YR AVG FCF Ratio 50.09 -9.37

Profitability (38%)

Company Industry
ROA (TTM) 4.57% -5.14%
ROE (TTM) 5.38% 16.69%
Net Profit Margin (TTM) 29.69% -1,583.93%
ROIC 5YR AVG 1.64% 15.15%

Growth (75%)

4QTR AVG 3YR AVG 5YR AVG
EPS -55.16% 788.81% 666.32%
Revenue 13.62% 17.16% -2.16%
Net Income -50.77% 750.93% 648.59%
Cash Flow 2,383.14% 71.77% 45.24%

Health (96%)

Company Industry
Current Ratio (TTM) 16.82 6.13
Quick Ratio (TTM) 15.70 5.85
D/E Ratio (TTM) 0.01 -15.81
Interest Coverage (TTM) 4.48 -1.57
Piotroski F-Score 6 5
Altman Z-Score 15.06 14.12
LTL to 5YR AVG FCF 0.14 0.17
Shares Outstanding Growth 5YR AVG -5.83% 123.44%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙